

# SmartPA Criteria Proposal

|                                   |  |
|-----------------------------------|--|
| <b>Drug/Drug Class:</b>           | Antifungal Agents – Topicals PDL Edit  |
| <b>First Implementation Date:</b> | July 10, 2014  |
| <b>Proposed Date:</b>             | March 19, 2020   |
| <b>Prepared For:</b>              | MO HealthNet   |
| <b>Prepared By:</b>               | MO HealthNet/Conduent  |
| <b>Criteria Status:</b>           | <input type="checkbox"/> Existing Criteria<br><input checked="" type="checkbox"/> Revision of Existing Criteria<br><input type="checkbox"/> New Criteria |

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** Many types of fungal germs (fungi) live harmlessly in the soil, on food, on our skin and in other places in the environment. However, some types of fungi can thrive and multiply on the surface of the body causing infection of the skin, nails, mouth or vagina. The most common fungi to cause skin infections are the tinea group of fungi. For example, tinea pedis (athlete's foot) is a common fungal infection of the toes and feet. Thrush is a common fungal infection of the mouth and vagina caused by an overgrowth of candida which is a yeast (a type of fungus). Small numbers of candida commonly live on the skin. However, certain conditions can cause candida to multiply and cause infection. Topical antifungals are used to treat these very common infections.

Total program savings for the PDL classes will be regularly reviewed.

### Program-Specific Information:

| Preferred Agents  | Non-Preferred Agents  |
|---|---|
| <ul style="list-style-type: none"> <li>• Butenafine Crm OTC</li> <li>• Ciclopirox 0.7% Crm/Soln/Susp</li> <li>• Clotrimazole Crm/Soln OTC</li> <li>• Clotrimazole/Betamethasone Crm</li> <li>• Ketoconazole Shampoo</li> <li>• Lamisil AT® Crm OTC</li> <li>• Miconazole Crm/Pwd OTC</li> <li>• Nystatin Crm/Oint/Pwd</li> <li>• Terbinafine Crm OTC</li> <li>• Tolnaftate Crm/Soln OTC</li> <li>• Zeasor®AF</li> </ul> | <ul style="list-style-type: none"> <li>• Alevazol® OTC</li> <li>• Aloe Vesta™ Oint</li> <li>• Azolen™ Tincture OTC</li> <li>• Ciclodan®</li> <li>• Ciclopirox 0.77% Gel</li> <li>• Ciclopirox 1% Shampoo</li> <li>• Ciclopirox 8% Kit/Soln</li> <li>• Clotrimazole Crm/Soln Rx</li> <li>• Clotrimazole Oint OTC</li> <li>• Clotrimazole/Betamethasone Lot</li> <li>• DermacinRx® Therazole™ Pak</li> <li>• Desenex®</li> <li>• Econazole</li> <li>• Ecoza™ Foam</li> <li>• Ertaczo®</li> <li>• Exelderm®</li> <li>• Extina®</li> <li>• Jublia®</li> </ul> |

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

|  |  |
|--|--|
|  | <ul style="list-style-type: none"> <li>• Kerydin™</li> <li>• Ketoconazole Crm/Foam</li> <li>• Ketodan®</li> <li>• Lamisil Ultra® OTC</li> <li>• Lamisil® Gel/Spray OTC</li> <li>• Loprox®</li> <li>• Lotrimin® AF Crm OTC</li> <li>• Lotrisone®</li> <li>• Luliconazole</li> <li>• Luzu®</li> <li>• Mentax®</li> <li>• Miconazole Nitrate Tincture/Kit OTC</li> <li>• Miconazole Spray OTC</li> <li>• Miconazole-Zinc-Petro 0.25-15%</li> <li>• Naftifine</li> <li>• Naftin®</li> <li>• Nizoral® AD</li> <li>• Nizoral®</li> <li>• Nystatin/Triamcinolone</li> <li>• Oxiconazole</li> <li>• Oxistat®</li> <li>• Penlac®</li> <li>• Tinactin®</li> <li>• Tolnaftate Pwd/Spray OTC</li> <li>• Triple Paste AF®</li> <li>• Vusion®</li> <li>• Xolegel®</li> </ul> |
|--|--|

Type of Criteria:  Increased risk of ADE  
 Appropriate Indications

Preferred Drug List  
 Clinical Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Antifungal Agents - Topical
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 4 or more preferred agents
  - Documented trial period of preferred agents
  - Documented ADE/ADR to preferred agents

## Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if no approval criteria are met

### SmartPA PDL Proposal Form

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

1 year

## References

1. Evidence-Based Medicine and Fiscal Analysis: "Topical Antifungals - Topical Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; January 2020.
2. Evidence-Based Medicine Analysis: "Topical Antifungal Agents", UMKC-DIC; Updated January 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

### *SmartPA PDL Proposal Form*

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.